Lupin Limited has notified its members about the opening of a special window for the transfer and dematerialization of physical shares, as mandated under SEBI Circular No. HO/38/13/11(2)2026-MIRSD-POD/I/3750/2026 dated January 30, 2026. The advertisement was published in Business Standard (English) and Mumbai Lakshdeep (Marathi) on May 05, 2026, pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Special Window Details

The special window has been opened for a period of one year, covering physical securities that were sold or purchased prior to April 01, 2019. The key parameters of this special window are outlined below:

Eligibility and Re-lodgement Process

Transfer requests that were previously submitted but were rejected, returned, or not attended to due to deficiency in documents, process, or otherwise, are required to be re-lodged during the window period with Lupin's Registrar and Transfer Agent (RTA), MUFG Intime India Pvt. Ltd. Members are advised that transfer requests lodged or re-lodged after the stipulated date of February 4, 2027 will not be entertained.

Post-Transfer Conditions

Upon successful transfer, where all documents are found to be in order, shares will be credited to the Transferee exclusively in dematerialized (demat) mode. The following conditions apply post-transfer:

• Transferred shares will be placed under a lock-in period of one year from the date of registration of transfer
• Such securities shall not be transferred, lien-marked, or pledged during the lock-in period
• The Transferee must open or maintain a demat account and submit the Client Master List (CML), not older than 2 months, duly attested by the Depository Participant, along with transfer documents, original share certificate, and an undertaking in the prescribed format

Cases Excluded from the Special Window

The following cases will not be considered under this special window:

• Cases involving disputes between transferor and transferee
• Securities that have been transferred to the Investor Education and Protection Fund (IEPF)

Regulatory Compliance

The notice was filed with the National Stock Exchange of India Limited and BSE Limited on May 05, 2026, and was signed by Amit Kumar Gupta, Company Secretary & Compliance Officer (ACS-15754) of Lupin Limited. The company's registered office is located at Kalpataru Inspire, 3rd Floor, Off Western Express Highway, Santacruz (East), Mumbai – 400055. Members requiring further information may contact the RTA at 810 811 6767 or at investor.helpdesk@in.mps.mufg.com .

Lupin Limited has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application (ANDA) for Glycerol Phenylbutyrate Oral Liquid, 1.1 grams per mL. The announcement was made on May 5, 2026, as part of a disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Product Overview

The approved product, Glycerol Phenylbutyrate Oral Liquid, 1.1 grams per mL, is bioequivalent to the reference listed drug (RLD) Ravicti® Oral Liquid, 1.1 grams per mL, of Horizon Therapeutics U.S. Holding LLC. The following table summarizes the key details of the approved product:

Therapeutic Indication

Glycerol Phenylbutyrate Oral Liquid is indicated for the chronic management of patients with urea cycle disorders (UCDs) that cannot be managed by dietary protein restriction and/or amino acid supplementation alone. UCDs are a group of metabolic conditions that affect the body's ability to process nitrogen, requiring specialized pharmaceutical intervention for long-term management.

Market Context

According to IQVIA MAT DEC 2025 data, product sales for Glycerol Phenylbutyrate Oral Liquid — referencing the RLD Ravicti® — stood at USD 337 million for the year ended December 2025. This figure reflects the scale of the addressable market that Lupin's newly approved generic product will compete in within the United States.

About Lupin Limited

Lupin Limited is a global pharmaceutical company headquartered in Mumbai, India, with products distributed in over 100 markets. The company specializes in branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women's health. Key operational highlights include:

• 15 state-of-the-art manufacturing sites globally
• 7 research centers globally
• A dedicated workforce of over 24,000 professionals
• Subsidiaries: Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions

Note: Ravicti® is the registered trademark of Horizon Therapeutics U.S. Holding LLC, a subsidiary of Amgen Inc.